Athena Athena

X
[{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Exalys Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The new company is focused on the development of first-in-class therapies for the treatment of inflammatory disorders with an initial target indication of the prevention of postoperative delirium.

            Lead Product(s): Undisclosed

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Catalys Pacific

            Deal Size: $15.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY